Use of Carbamazepine in Acute Psychosis: A Controlled Study

Lenzi, A.; Lazzerini, F.; Grossi, Enzo; Massimetti, Gabriele; Placidi, G. F.

doi:10.1177/030006058601400205

Cited by 33 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbamazepine seems to exert an acute antimanic effect (e.g. 16–21). The efficacy of OXC in bipolar disorder has been suggested already in some trials in acute mania (22–24).…”

mentioning

confidence: 99%

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off‐on design

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Carbamazepine seems to exert an acute antimanic effect (e.g. 16–21). The efficacy of OXC in bipolar disorder has been suggested already in some trials in acute mania (22–24).…”

mentioning

confidence: 99%

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off‐on design

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Particularly in the uncontrolled studies, carbamazepine has often been added to previously ineffective regimens including lithium carbonate. The adequacy of carbamazepine alone in comparison to lithium has been reported in more recent studies (Bellaire et al, 1988;Lusznat et al, 1988;Watkins et al, 1987;Placidi et al, 1986), but still requires further c1arification. Moreover, the issue of whether there are differential subgroups of responders to one drug compared to the other also requires further study.…”

Section: The Anticonvulsant Carbamazepine In Affective Illnessmentioning

confidence: 84%

Sensitization and Kindling Perspectives for the Course of Affective Illness: Toward a New Treatment with the Anticonvulsant Carbamazepine

1990

Pharmacopsychiatry

View full text Add to dashboard Cite

Successive episodes of affective illness often show an accelerating frequency of recurrence. Two very different preclinical models (behavioral sensitization to psychomotor stimulants and electrophysiological kindling) may be used as indirect analogies or non-homologous models for conceptualizing mechanisms underlying the progressive and evolving aspects of manic-depressive illness. These models focus on phenomena involved in the longitudinal course of illness and on novel treatment implications. Literature is reviewed on the acute and long-term effectiveness of the anti-convulsant carbamazepine, particularly in treatment of lithium-refractory bipolar illness. Potential mechanisms of carbamazepine's acute anticonvulsant and antinociceptive and delayed psychotropic actions are discussed. alpha-2 adrenergic and peripheral-type benzodiazepine receptors, and stabilization of type-2 sodium channels are likely involved in the anticonvulsant effects of carbamazepine. GABAB mechanisms are thought to be related to the antinociceptive but not anticonvulsant or psychotropic effects of carbamazepine. A large number of neurotransmitters remain candidates for the psychotropic effects and a novel animal model requiring chronic administration of carbamazepine in order to show efficacy is reported (Weiss et al., 1989). It is hoped that further understanding of the mechanism of action of the anti-convulsant agents in comparison and contrast with traditional psychotropic agents will help in generating new treatments and in uncovering the basic defects of manic-depressive illness.

show abstract

“…At least 12 double-blind randomised controlled trials were reported in the '80s and early '90s, showing that carbamazepine is superior to placebo and comparable to lithium and antipsychotics in the treatment of acute mania [72][73][74][75][76][77][78][79][80][81][82][83]. However, only six of these studies [72-75, 78, 83] have not been biased by the concomitant use of lithium and antipsychotics.…”

Section: Carbamazepinementioning

confidence: 99%

Antiepileptic drugs: indications other than epilepsy

Spina,

Perugi

2004

Epileptic Disorders

117

View full text Add to dashboard Cite

Antiepileptic drugs (AEDs) are increasingly used for the treatment of several non‐epileptic neurological conditions and psychiatric disorders. Most of the information available on the use of these agents in clinical disorders outside epilepsy is from case series, uncontrolled studies or small randomised clinical trials, and their apparent efficacy requires confirmation through well designed, large, phase III trials. With regard to neurological conditions other than epilepsy, experimental evidence for the efficacy of AEDs is only available for the treatment of patients with trigeminal neuralgia, neuropathic pain syndromes, migraine and essential tremor. Carbamazepine is commonly prescribed as first‐line therapy for patients with trigeminal neuralgia. Gabapentin has been recently marketed for the management of neuropathic pain syndromes, particularly diabetic neuropathy and postherpetic neuralgia. Valproic acid (sodium valproate), in the form of divalproex sodium, is approved for migraine prophylaxis. Primidone can be considered a valuable option for the treatment of essential tremor. AEDs are also used to treat psychiatric conditions, in particular bipolar disorder. So far, the most commonly utilized AEDs in the treatment of this disorder have been carbamazepine and valproic acid, which have showed an antimanic efficacy and a probable long‐term, mood‐stabilizing effect in many bipolar patients, including those refractory or intolerant to lithium. The availability of a new generation of AEDs has broadened the therapeutic options in bipolar disorder. Lamotrigine, oxcarbazepine, gabapentin and topiramate appear to be promising in the treatment of refractory bipolar disorder, as a monotherapy as well as in combination with traditional mood stabilizers. In addition, newer AEDs appear to have a more favourable tolerability and drug interaction profile as compared to older compounds, so thus improving compliance to treatment.

show abstract

Use of Carbamazepine in Acute Psychosis: A Controlled Study

Cited by 33 publications

References 6 publications

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off‐on design

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on‐off‐on design

Sensitization and Kindling Perspectives for the Course of Affective Illness: Toward a New Treatment with the Anticonvulsant Carbamazepine

Antiepileptic drugs: indications other than epilepsy

Contact Info

Product

Resources

About